SRX Global to acquire CERo Therapeutics for stock and ~$9.8M debt forgiveness

SRX Global signed a definitive agreement to acquire CERo Therapeutics' operating subsidiary from its parent CERo Therapeutics Holdings, with consideration consisting of $1M in SRXH stock (at lower of prior-day close or 20-day VWAP), forgiveness of $8.25M in outstanding debt plus accrued interest, and assumption of ~$1.56M in liabilities. The transaction is subject to a 30-day go-shop period and superior proposal rights, creating execution risk through at least mid-March 2027.

SRXH is buying another company for mostly a debt write-off and some of its own stock, but the deal can still be shopped around for 30 days—so it might not happen or the terms could change.